title: Lutropin alfa.
abstract: Lutropin alfa is the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. Dose-finding studies revealed a significant dose-dependent increase in the rate of optimal follicular development among women with hypogonadotropic hypogonadism and profound LH deficiency (<1.2 IU/L) who received subcutaneous lutropin alfa 0-225 IU/day plus follitropin alfa. Similarly, in a double-blind, randomized study, the rate of optimal follicular development was significantly higher in women with hypogonadotropic hypogonadism and profound LH deficiency receiving subcutaneous lutropin alfa 75 IU/day plus follitropin alfa than in those receiving placebo plus follitropin alfa. Lutropin alfa with follitropin alfa may also be of benefit in certain subgroups of normogonadotropic women (e.g. those with an inadequate response to prior follitropin alfa monotherapy, those aged >or=35 years, and those with profound LH downregulation or who required excessive exogenous follitropin alfa). However, one study in older women (>or=35 years) did not show any advantage of lutropin alfa supplementation. Once-daily subcutaneous lutropin alfa was generally well tolerated in hypogonadotropic hypogonadal women, with the majority of adverse events being of mild to moderate severity.
authors.affiliation: Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Sohita
authors.initials: S
authors.lastname: Dhillon
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
mesh_terms: D004359:Drug Therapy, Combination; D005260:Female; D005300:Fertility Agents, Female / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D043373:Follicle Stimulating Hormone, Human / Q000627:therapeutic use; D015292:Glycoprotein Hormones, alpha Subunit / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D007247:Infertility, Female / Q000188:drug therapy; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000172:deficiency; D010062:Ovulation Induction / Q000379:methods; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; D015292:Glycoprotein Hormones, alpha Subunit; D011994:Recombinant Proteins; D007986:Luteinizing Hormone